P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer

G. Gasparini, P. Bevilacqua, F. Pozza, S. Meli, N. Weidner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This study was undertaken to define the role of P-glycoprotein (P-glyc), as a marker of multidrug resistance (MDR) and to determine if it would predict both response to chemotherapy and prognosis in 42 previously untreated patients with advanced breast carcinoma. P-glyc was assayed using the monoclonal antibody (Mab) JSB-1 using an immunocytochemical method. On the same tumours, the following biological features were also estimated: tumour angiogenesis, epidermal growth factor receptor, c-erbB-2 oncoprotein and growth fraction using immunohistochemistry with immunocytochemically factor VIII-related antigen, EGFR1 Mab, 21N antibody and Ki-67 Mab, respectively. Overall, 50% of carcinomas were JSB-1 positive and the presence of P-glyc was not significantly associated with any other factor, but it was significantly predictive of poor response with anthracycline based chemotherapy (p=0.03). Moreover, lack of initial response to chemotherapy was significantly correlated with the percentage of cells staining with the JSB-1 antibody (p=0.016). P-glyc expression and the proportion of cells staining as JSB-1 positive correlated with clinical stage and analysis showed that they significantly predicted response to chemotherapy only in stage IV patients (p=0.015 and p

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalBreast
Volume2
Issue number1
DOIs
Publication statusPublished - 1993

Fingerprint

P-Glycoprotein
Breast Neoplasms
Drug Therapy
Monoclonal Antibodies
Staining and Labeling
Antibodies
Anthracyclines
Oncogene Proteins
von Willebrand Factor
Multiple Drug Resistance
Epidermal Growth Factor Receptor
Neoplasms
Immunohistochemistry
Carcinoma
Growth

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer. / Gasparini, G.; Bevilacqua, P.; Pozza, F.; Meli, S.; Weidner, N.

In: Breast, Vol. 2, No. 1, 1993, p. 27-32.

Research output: Contribution to journalArticle

Gasparini, G. ; Bevilacqua, P. ; Pozza, F. ; Meli, S. ; Weidner, N. / P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer. In: Breast. 1993 ; Vol. 2, No. 1. pp. 27-32.
@article{4201828700144253bbd8cec50d946313,
title = "P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer",
abstract = "This study was undertaken to define the role of P-glycoprotein (P-glyc), as a marker of multidrug resistance (MDR) and to determine if it would predict both response to chemotherapy and prognosis in 42 previously untreated patients with advanced breast carcinoma. P-glyc was assayed using the monoclonal antibody (Mab) JSB-1 using an immunocytochemical method. On the same tumours, the following biological features were also estimated: tumour angiogenesis, epidermal growth factor receptor, c-erbB-2 oncoprotein and growth fraction using immunohistochemistry with immunocytochemically factor VIII-related antigen, EGFR1 Mab, 21N antibody and Ki-67 Mab, respectively. Overall, 50{\%} of carcinomas were JSB-1 positive and the presence of P-glyc was not significantly associated with any other factor, but it was significantly predictive of poor response with anthracycline based chemotherapy (p=0.03). Moreover, lack of initial response to chemotherapy was significantly correlated with the percentage of cells staining with the JSB-1 antibody (p=0.016). P-glyc expression and the proportion of cells staining as JSB-1 positive correlated with clinical stage and analysis showed that they significantly predicted response to chemotherapy only in stage IV patients (p=0.015 and p",
author = "G. Gasparini and P. Bevilacqua and F. Pozza and S. Meli and N. Weidner",
year = "1993",
doi = "10.1016/0960-9776(93)90033-C",
language = "English",
volume = "2",
pages = "27--32",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer

AU - Gasparini, G.

AU - Bevilacqua, P.

AU - Pozza, F.

AU - Meli, S.

AU - Weidner, N.

PY - 1993

Y1 - 1993

N2 - This study was undertaken to define the role of P-glycoprotein (P-glyc), as a marker of multidrug resistance (MDR) and to determine if it would predict both response to chemotherapy and prognosis in 42 previously untreated patients with advanced breast carcinoma. P-glyc was assayed using the monoclonal antibody (Mab) JSB-1 using an immunocytochemical method. On the same tumours, the following biological features were also estimated: tumour angiogenesis, epidermal growth factor receptor, c-erbB-2 oncoprotein and growth fraction using immunohistochemistry with immunocytochemically factor VIII-related antigen, EGFR1 Mab, 21N antibody and Ki-67 Mab, respectively. Overall, 50% of carcinomas were JSB-1 positive and the presence of P-glyc was not significantly associated with any other factor, but it was significantly predictive of poor response with anthracycline based chemotherapy (p=0.03). Moreover, lack of initial response to chemotherapy was significantly correlated with the percentage of cells staining with the JSB-1 antibody (p=0.016). P-glyc expression and the proportion of cells staining as JSB-1 positive correlated with clinical stage and analysis showed that they significantly predicted response to chemotherapy only in stage IV patients (p=0.015 and p

AB - This study was undertaken to define the role of P-glycoprotein (P-glyc), as a marker of multidrug resistance (MDR) and to determine if it would predict both response to chemotherapy and prognosis in 42 previously untreated patients with advanced breast carcinoma. P-glyc was assayed using the monoclonal antibody (Mab) JSB-1 using an immunocytochemical method. On the same tumours, the following biological features were also estimated: tumour angiogenesis, epidermal growth factor receptor, c-erbB-2 oncoprotein and growth fraction using immunohistochemistry with immunocytochemically factor VIII-related antigen, EGFR1 Mab, 21N antibody and Ki-67 Mab, respectively. Overall, 50% of carcinomas were JSB-1 positive and the presence of P-glyc was not significantly associated with any other factor, but it was significantly predictive of poor response with anthracycline based chemotherapy (p=0.03). Moreover, lack of initial response to chemotherapy was significantly correlated with the percentage of cells staining with the JSB-1 antibody (p=0.016). P-glyc expression and the proportion of cells staining as JSB-1 positive correlated with clinical stage and analysis showed that they significantly predicted response to chemotherapy only in stage IV patients (p=0.015 and p

UR - http://www.scopus.com/inward/record.url?scp=0027241335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027241335&partnerID=8YFLogxK

U2 - 10.1016/0960-9776(93)90033-C

DO - 10.1016/0960-9776(93)90033-C

M3 - Article

AN - SCOPUS:0027241335

VL - 2

SP - 27

EP - 32

JO - Breast

JF - Breast

SN - 0960-9776

IS - 1

ER -